NDA filed for non-hormonal menopause therapy
This article was originally published in Scrip
Executive Summary
Noven Pharmaceuticals has submitted a new drug application (NDA) to the US FDA seeking approval to market its investigational non-hormonal treatment for the vasomotor symptoms associated with menopause, low-dose mesylate salt of paroxetine (LDMP).